Loading
NKTR (NK-tumour recognition protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.
PPIase that catalyses the cis-trans isomerisation of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding. Component of a putative tumour-recognition complex involved in the function of NK cells.
IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Acute Myeloid Leukaemia.
In plain words · NKTR (NK-tumour recognition protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.
NKTR (NK-tumour recognition protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.
PPIase that catalyses the cis-trans isomerisation of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding. Component of a putative tumour-recognition complex involved in the function of NK cells.
No product in this corpus aims at NKTR yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 1993. Earliest sequence paper UniProt cites for the protein: Anderson S.K. et al, Proc. Natl. Acad. Sci. U.S.A, 1993, "A cyclophilin-related protein involved in the function of natural killer cells". Source.
Sources: HGNC HGNC:7833 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P30414 (protein name, function text, keywords and locations (REST API)); IntOGen NKTR (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
PPIase that catalyses the cis-trans isomerisation of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding. Component of a putative tumour-recognition complex involved in the function of NK cells. Location: Cell membrane (UniProt). Locus 3p22.1 (HGNC).
Query for this target: (TITLE:"NKTR" OR ABSTRACT:"NKTR" OR TITLE:"natural killer cell triggering receptor" OR ABSTRACT:"natural killer cell triggering receptor" OR TITLE:"NK-tumor recognition protein" OR ABSTRACT:"NK-tumor recognition protein" OR TITLE:"p104" OR ABSTRACT:"p104" OR TITLE:"CypNK" OR ABSTRACT:"CypNK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NKTR, not a curated reading list.
Shares A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma, A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC).